title: What is the current role of biologics in the management of patients with severe refractory asthma?
authors.affiliation: Rutgers University, New Jersey Medical School, Livingston, New Jersey. Electronic address: sdraikiw@gmail.com.
authors.forename: Steven
authors.initials: S
authors.lastname: Draikiwicz
authors.affiliation: Rutgers University, New Jersey Medical School, Livingston, New Jersey.
authors.forename: John
authors.initials: J
authors.lastname: Oppenheimer
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007378:Interleukins / Q000037:antagonists & inhibitors; D009330:Nebulizers and Vaporizers; D000069444:Omalizumab / Q000627:therapeutic use; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001688:Biological Products; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D000069444:Omalizumab; D007073:Immunoglobulin E